Galiximab Drug Asset Due Diligence Report 2026

This Galiximab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Galiximab can convert its Monoclonal antibody profile and CD80 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Galiximab (query alias: Galiximab)
Modality / target	Monoclonal antibody; CD80; CD80 inhibitors, Immunomodulators
Highest global status	Phase 2
Originator	Biogen, Inc.
Active developers	Hospital García IMSS, Biogen-Idec Pharmaceuticals, Inc.

The MCP disease footprint includes B-Cell Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT00651443	Phase 1	Terminated	20	Primary endpoint not disclosed in English source
NCT00575068	Phase 1/2	Completed	42	Primary endpoint not disclosed in English source
NCT00516217	Phase 2	Completed	30	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Phase 2; n=174; evaluation: Positive. Reported fields: OS(2-year) = 80 % ; OS(2-year) = 99 %

A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma

Phase 2; n=30; evaluation: Not stated in English source. Reported fields: ORR = 3 Pts

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Phase 2; n=61; evaluation: Positive. Reported fields: mPFS = 2.9 Year

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Galiximab addresses B-Cell Lymphoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 12 matched transaction record(s) under the scope “target-level comparable: CD80.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD80 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2024-05-28	BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	Preclinical	Financial terms not disclosed
2023-03-20	Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases	Preclinical	Financial terms not disclosed
2021-03-23	The Zenas pipeline also includes three potentially best-in-class mAbs (ZB002, ZB003, ZB004) exclusively in-licensed worldwide from Xencor, Inc.	Phase 2	US$480.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Modified Cytotoxic T Cells and Methods of Use Thereof”. The milestone feed surfaced a patent-application signal described as “Multi-specific self-assembled drug-free macromolecular t-cell engagers”. The milestone feed surfaced a patent-application signal described as “Compositions and methods for inducing viral mimicry in cancer cells”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO